However, these benefits are blurred ...

Pneumococcus vaccines from James C. Paton

writing into existing against pneumococcus capsule oriented (PS), of which there are 91 different serotypes. Purified polyvalent PS vaccine immunogenic in healthy adults, but not in high-risk groups such as young children and the elderly. The development of PS-protein conjugate vaccine overcome the poor immunogenicity of the PS in children, but the defense gave a strictly serotype-specific, and the number of serotypes included even more limited than in the PS vaccine formulations. The widespread introduction of conjugate vaccines in developed countries drastically reduces the incidence of invasive pneumococcal disease due to serotypes included in the vaccine. However, these benefits are eroded by increasing the number of cases caused by vaccine serotypes not. The conjugate vaccine is also expensive, which limits their use in developing countries where the burden of pneumococcal disease is greatest. Obviously, there is an urgent need to develop alternative pneumococcal strattera prescription vaccine, which (I), inexpensive, (II) immunogenic in young children, and (III) provide protection against all pneumococci, irrespective of serotype. Of particular importance are the pneumococcal vaccine contains proteins that contribute to virulence and are common to all serotypes. Additional information: | Keywords: | | | | | | | | | | | |